A drug-resistant fungus that barely existed a decade ago has infected more than 13,500 Americans in just three years, and federal health officials say the numbers keep climbing.
Quick Take
- Candida auris clinical cases in the United States jumped from 2,882 in 2022 to 6,197 in 2024, according to Centers for Disease Control and Prevention (CDC) surveillance.
- The fungus can resist multiple antifungal drug classes, with CDC lab testing showing 93% of isolates resistant to the common drug fluconazole.
- The World Health Organization (WHO) named Candida auris one of four “critical priority” fungal pathogens on its global threat list.
- Experts point to warming temperatures and heavy antifungal use as likely drivers, though the exact causes are still being studied.
- The fungus spreads mainly in hospitals and nursing homes, making infection control the front line of defense.
Case Counts Have More Than Doubled Since 2022
CDC surveillance data show a steep climb in Candida auris infections nationwide. Clinical cases rose from 2,882 in 2022 to 4,428 in 2023, then to 6,197 in 2024. That adds up to 13,507 reported cases over three years, and the agency says the upward trend stretches back even further, to 2016.
The fungus was unknown to science until 2009. Within a decade it had spread across several continents in genetically distinct versions, a pattern that caught infectious-disease researchers off guard. It now shows up regularly in American hospitals and long-term care facilities, where CDC describes it as a yeast capable of spreading quickly among vulnerable patients.
Health officials stress that the fungus mostly threatens people who are already sick or hospitalized. Healthy people rarely catch it. But for patients with weakened immune systems, feeding tubes, or breathing tubes, an infection can turn deadly fast, since treatment options are limited once resistance sets in.
Drug Resistance Is Real, But Not Absolute
CDC lab data put numbers behind the resistance problem. Out of 22,532 tested isolates, 93.25% resisted fluconazole, a go-to antifungal drug. That is a staggering figure. But resistance to echinocandins, a stronger backup class of drugs, showed up in only 1.19% of 24,301 isolates tested.
That gap matters. It means most infections can still be treated, just with fewer and more expensive options. Multidrug-resistant strains, resistant to azoles, echinocandins, and polyenes all at once, have been detected in the United States. Those cases remain rare, but CDC flags them as a serious warning sign for the future.
The Seattle Times reported on CDC’s broader warning about which superbugs pose the biggest danger to Americans, placing Candida auris alongside bacterial threats that already kill thousands of people each year. The agency’s wider Antimicrobial Resistance Threats work tracks these pathogens together, treating fungal resistance as part of the same emergency as drug-resistant bacteria.
A Global Priority List and a Climate Question
The World Health Organization built its first-ever Fungal Priority Pathogens List in 2022, naming 19 fungi that pose major risks to public health. Candida auris landed in the top tier, alongside Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans.
Researchers studying the list believe some fungi, including Candida auris, emerged and spread partly because of a warming climate. The idea is that rising temperatures may be pushing fungi to adapt to heat levels closer to the human body, making it easier for them to survive and infect people. That theory has real scientific backing, but it is still an emerging area of study rather than a fully settled explanation.
Antifungal overuse, in hospitals, farms, and everyday medicine, is also suspected of helping resistant strains develop. Overprescribing and heavy agricultural chemical use create the exact conditions that let dangerous microbes outsmart our best drugs. That lesson applies just as much to fungi as it does to bacteria.
None of this means panic is warranted. Candida auris remains concentrated in healthcare settings, and most Americans will never encounter it. But the trend lines are clear, the resistance data are documented, and public health agencies on both sides of the Atlantic are treating it as a priority worth watching closely.
Sources:
time.com, cdc.gov, pmc.ncbi.nlm.nih.gov, stacks.cdc.gov, seattletimes.com
